Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mode of Induction in Fetal Growth Restriction
NCT03625518Phase 1Unknown
- Sponsor
- Tel Aviv Sourasky Medical Center
- Start
- Sep 2018
- Primary completion
- Jul 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dinoprostone and oxytocin in fetal growth restriction (FGR) (2 arms), sponsored by Tel Aviv Sourasky Medical Center. Primary endpoint: mode of delivery. Status: unknown.
02
Drugs
dinoprostoneoxytocin
03
Conditions
fetal growth restriction (FGR)
Beyond the preview
Go deeper on NCT03625518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03625518.